Related Experiment Video
Updated: Oct 2, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Treatment of heart failure in patients with diabetes: clinical update
1Division of Endocrinology and Metabolism, The University of Alabama at Birmingham, School of Medicine, USA. dbell@endo.dom.uab.edu
Insights
Diabetic patients face higher heart failure (HF) risks and worse outcomes. Aggressive diagnosis and management, including specific medications like carvedilol, are crucial for improving survival in these individuals.
Area of Science:
- Cardiology
- Endocrinology
- Diabetology
Background:
- Heart failure (HF) is more prevalent and severe in diabetic patients.
- Diabetic cardiomyopathy exacerbates HF risks from hypertension and coronary heart disease.
- Diabetes contributes to systolic and diastolic dysfunction, worsening HF prognosis.
Purpose of the Study:
- To highlight the increased prevalence and mortality of HF in diabetes.
- To emphasize the need for aggressive HF diagnosis and management in diabetic individuals.
- To discuss effective HF treatment strategies in the context of diabetes.
Main Methods:
- Review of existing literature on heart failure in diabetic populations.
- Analysis of risk factors including hypertension, coronary heart disease, and diabetic cardiomyopathy.
- Evaluation of established HF treatments and their efficacy in diabetics.
Main Results:
- Diabetic patients exhibit higher HF prevalence and mortality.
- Diabetic cardiomyopathy, hypertension, and coronary heart disease increase HF risk.
- Standard HF treatments (ACE inhibitors, beta-blockers) are effective; glycemic control is vital.
Conclusions:
- Aggressive HF diagnosis and management are essential for diabetic patients, even if asymptomatic.
- Carvedilol may mitigate adverse metabolic effects of beta-blockade in diabetics.
- Integrated management of diabetes and HF is critical for improved patient outcomes.
Abstract:
Heart failure is an important problem for the growing number of persons afflicted with diabetes. Not only is HF more prevalent than in the non-diabetic population but also it carries a graver prognosis. Diabetic cardiomyopathy adds to the already increased risks for developing HF with hypertension and coronary heart disease, leading to systolic and diastolic dysfunction. As LV function deteriorates, increases in RAS and SNS activation may lead to progressive HF and premature death. The greater prevalence and increased mortality risk in diabetic patients supports the role of aggressive HF diagnosis and management, even in asymptomatic patients. Treatment strategies already established for HF have been shown to be effective in the diabetic population, including ACE inhibitors and beta-blockers. There is evidence that glycemic control is also important in improving clinical outcomes. The adverse effects of beta-blockade on carbohydrate and lipid metabolism and vasoconstriction may be circumvented by the use of carvedilol.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions
Heart Failure Drugs: Diuretics
Heart Failure III: Clinical Manifestations